Keros Therapeutics, Inc. (KROS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 15.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $15.01M | (m) | (m) |
| 2026-03-31 | (m) | $33.18M | (m) | (m) |
| 2025-12-31 | (m) | $244.06M | (m) | (m) |
| 2025-09-30 | (m) | $246.72M | (m) | (m) |
| 2025-06-30 | (m) | $232.84M | (m) | (m) |
| 2025-03-31 | (m) | $214.71M | (m) | (m) |
| 2024-12-31 | (m) | $3.55M | (m) | (m) |
| 2024-09-30 | (m) | $651.00K | (m) | (m) |
| 2024-06-30 | (m) | $271.00K | (m) | (m) |
| 2024-03-31 | (m) | $234.00K | (m) | (m) |
| 2023-12-31 | (m) | $151.00K | (m) | (m) |
| 2023-09-30 | (m) | $8.00K | (m) | (m) |
| 2023-06-30 | (m) | $0.00 | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $0.00 | (m) | (m) |
| 2022-09-30 | (m) | $20.00M | (m) | (m) |
| 2022-06-30 | (m) | $20.00M | (m) | (m) |
| 2021-12-31 | (m) | $20.10M | (m) | (m) |
| 2021-09-30 | (m) | $100.00K | (m) | (m) |
| 2021-06-30 | (m) | $100.00K | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $10.00M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |